Axsome Therapeutics Statistics
Want to see AXSM full AI Analyst Report?
Axsome Therapeutics (AXSM) Stock Statistics & Valuation Metrics
Total Valuation
Axsome Therapeutics has a market cap or net worth of $7.42B. The enterprise value is $9.58B.
- Market Cap
- $7.42B
- Enterprise Value
- $9.58B
Share Statistics
Axsome Therapeutics has 52,599,983 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 52,599,983
- Owned by Insiders
- 15.02%
- Owned by Institutions
- 40.08%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -2.07 and return on invested capital (ROIC) is -43.95%.
- Return on Equity (ROE)
- -2.07
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -43.95%
- Return on Capital Employed (ROCE)
- -0.54
- Revenue Per Employee
- 474.37K
- Profits Per Employee
- -136.09K
- Employee Count
- 1,346
- Asset Turnover
- 0.93
- Inventory Turnover
- 1.70
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is -46.07. Axsome Therapeutics’s PEG ratio is -1.13.
- PE Ratio
- -46.07
- PS Ratio
- 8.57
- PB Ratio
- 70.12
- Price to FCF
- -89.76
- Price to Operating Cash Flow
- -90.41
- PEG Ratio
- -1.13
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 638.50M and earned -183.17M in profits. Earnings per share was -3.68.
- Revenue
- 638.50M
- Gross Profit
- 591.02M
- Operating Income
- -169.24M
- Pretax Income
- -183.70M
- Net Income
- -183.17M
- EBITDA
- -168.08M
- Earnings Per Share (EPS)
- -3.68
Cash Flow
In the last 12 months, operating cash flow was -81.77M and capital expenditures -839,000, giving a free cash flow of -82.61M billion.
- Operating Cash Flow
- -81.77M
- Free Cash Flow
- -82.61M
- Free Cash Flow per Share
- -1.58
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.14%
- Earnings Yield
- -2.17%
Stock Price Statistics
- Beta
- 0.90
- 52-Week Price Change
- 2.30%
- 50-Day Moving Average
- 177.77
- 200-Day Moving Average
- 198.43
- Relative Strength Index (RSI)
- 37.64
- Average Volume (3m)
- 844.07K
Important Dates
Axsome Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Axsome Therapeutics as a current ratio of 1.55, with Debt / Equity ratio of 273.28%
- Current Ratio
- 1.55
- Quick Ratio
- 1.48
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- -25.81
Taxes
In the past 12 months, Axsome Therapeutics has paid -530.00K in taxes.
- Income Tax
- -530.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -50.00, with an EV/FCF ratio of -86.85.
- EV to Sales
- 8.29
- EV to EBITDA
- -50.00
- EV to Free Cash Flow
- -86.85
- EV to Operating Cash Flow
- -87.74
Balance Sheet
Axsome Therapeutics has $313.86M in cash and marketable securities with $218.67M in debt, giving a net cash position of $95.19M billion.
- Cash & Marketable Securities
- $313.86M
- Total Debt
- $218.67M
- Net Cash
- $95.19M
- Net Cash Per Share
- $1.81
- Tangible Book Value Per Share
- $1.10
Margins
Gross margin is 93.25%, with operating margin of -17.74%, and net profit margin of -18.18%.
- Gross Margin
- 93.25%
- Operating Margin
- -17.74%
- Pretax Margin
- -18.10%
- Net Profit Margin
- -18.18%
- EBITDA Margin
- -16.58%
- EBIT Margin
- -17.45%
Analyst Forecast
The average price target for Axsome Therapeutics is $260.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $260.42
- Price Target Upside
- 84.74% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 19
- Revenue Growth Forecast
- 54.16%
- EPS Growth Forecast
- 34.51%
Scores
- Smart Score
- 4
- AI Score
- 47
